The U.S. Food and Drug Administration (FDA) has unveiled a sweeping transparency initiative that will fundamentally change how innovative drug and biologic developers interface with the Agency and the market. ...more
9/8/2025
/ Abbreviated New Drug Application (ANDA) ,
Biologics ,
Disclosure Requirements ,
Food and Drug Administration (FDA) ,
Healthcare ,
Life Sciences ,
New Regulations ,
Pharmaceutical Industry ,
Regulatory Oversight ,
Regulatory Reform ,
Risk Management